Fear of MOVEment After MI and AF - InterneT Patient Education
Launched by LINKOEPING UNIVERSITY · Oct 10, 2023
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Fear of MOVEment After MI and AF - InterneT Patient Education," is exploring whether online group education can help patients who have had a heart attack (myocardial infarction or MI) or an irregular heartbeat (atrial fibrillation or AF) feel less fearful about moving and encourage them to be more active. The study aims to see if participating in digital education sessions can reduce their fear of physical activity, known as kinesiophobia, and promote a healthier lifestyle.
Eligible participants are adults aged 65 and older who have experienced a heart event (MI or AF) and have a kinesiophobia score above 37, meaning they have significant fear of movement. Those selected will join a series of seven online meetings over eight weeks, where they will learn about safe physical activity, the conditions affecting their heart, and strategies to overcome their fears. This program is designed to be engaging and supportive, using real-life scenarios and interactive discussions to help patients feel more comfortable and confident in being active again.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients (n=16 with MI and/or AF with kinesiophobia score of \> 37.
- • Recruitment: around six months after the heart event (MI and or/AF)
- Exclusion Criteria:
- • ongoing investigation of coronary artery disease and/or atrial fibrillation or other disease that results in a negative prognosis within 1 year.
- • patients who have difficulty participating in and cooperating with other people in groups due to, for example, mental illness, obvious abuse of alcohol or drugs, difficulties communicating or reading the Swedish language,
- • or participation in other studies that may affect the results are excluded.
About Linkoeping University
Linköping University is a leading academic institution in Sweden, renowned for its innovative research and commitment to advancing medical science. With a strong emphasis on interdisciplinary collaboration, the university facilitates cutting-edge clinical trials aimed at improving patient outcomes and enhancing healthcare delivery. Linköping University’s research initiatives are supported by state-of-the-art facilities and a robust network of partnerships with healthcare providers, industry stakeholders, and regulatory bodies, ensuring rigorous methodologies and ethical standards in all clinical investigations. Through its dedication to research excellence, Linköping University plays a pivotal role in translating scientific discoveries into practical applications that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Norrköping, Ostergotland, Sweden
Patients applied
Trial Officials
Anita Kärner Köhler, Ass. prof
Principal Investigator
Linkoping University, Dept of Health, Medicine and Care
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported